Tengion, which is developing functional neo-organs using a patient's own cells, will see its quiet period end on Tuesday, May 18th. On April 4th, the company raised $30 million by offering 6 million shares at $5, below the range of $8-$10. Piper Jaffray and Leerink Swann acted as lead managers on the deal.
